Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells

Histology and Histopathology

Volumn 22, Issue 4-6, 2007, Pages 437-442

  Adachi, Masaaki ^a   Sakamoto, H ^a   Kawamura, R ^a   Wang, W ^a   Imai, K ^a   Shinomura, Y ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

DNA damage; NSAIDs; ROS

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BORTEZOMIB; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSI 461; OSIP 486823; OSIP 487703; PARTHENOLIDE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; THALIDOMIDE; THROMBOXANE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER PREVENTION; CELL CYCLE ARREST; COLON CANCER; COLORECTAL ADENOMA; DNA DAMAGE; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; LIPID PEROXIDATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMOPROPHYLAXIS; DRUG EFFECT; FEMALE; MALE; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHEMOPREVENTION; DNA DAMAGE; FEMALE; HUMANS; MALE; NEOPLASMS; OXIDATIVE STRESS; SULINDAC;

EID: 33947545295     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Blau S., Rubinstein A., Bass P., Singaram C. and Kohen R. (1999). Differences in the reducing power along the rat GI tract: lower antioxidant capacity of the colon. Mol. Cell Biochem. 194, 185-191.
2. Bresalier R.S. (2002). Primary chemoprevention of familial adenomatous polyposis with sulindac: more questions than answers. Gastroenterology 123, 379-381.
3. Chan T.A., Morin P.J., Vogelstein B. and Kinzler K.W. (1998). Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA 95, 681-686.
4. Chen Q., Chai Y.C., Mazumder S., Jiang C., Macklis R.M., Chisolm G.M. and Almasan A. (2003). The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ. 10, 323-334.
5. Chung Y.M., Bae Y.S. and Lee S.Y. (2003). Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. Free Radic. Biol. Med. 34, 434-442.
6. Costa D., Gomes A, Reis S, Lima J.L. and Fernandes E. (2005). Hydrogen peroxide scavenging activity by non-steroidal anti-inflammatory drugs. Life Sci. 76, 2841-2848.
7. Fernandes E., Toste S.A., Lima J.L. and Reis S. (2003). The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radic. Biol. Med. 35, 1008-1017.
8. Giardina C. and Inan M.S. (1998). Nonsteroidal anti-inflammatory drugs, short-chain fatty acids, and reactive oxygen metabolism in human colorectal cancer cells. Biochim. Biophys. Acta 1401, 277-288.
9. Giardina C., Boulares H. and Inan M.S. (1999). NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. Biochim. Biophys. Acta 1448, 425-438.
10. Grosch S., Tegeder I., Niederberger E., Brautigam L. and Geisslinger G. (2001). COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15, 2742-2744.
11. Haanen C. (2001). Sulindac and its derivatives: a novel class of anticancer agents. Curr. Opin. Investig. Drugs. 2, 677-683.
12. Helbock H.J., Beckman K.B. and Ames B.N. (1999). 8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage. Methods Enzymol. 300, 156-166.
13. Hileman E.O., Liu J., Albitar M., Keating M.J. and Huang P. (2004). Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother. Pharmacol. 53, 209-219.
14. Huang H.L., Fang LW., Lu S.P., Chou C.K., Luh T.Y and Lai M.Z. (2003). DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 22, 8168-8177.
15. Hsu C.S. and Li Y. (2002). Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention. Biochem. Biophys. Res. Commun. 293, 705-709.
16. Janne P.A. and Mayer R.J. (2000). Chemoprevention of colorectal cancer. N. Engl. J. Med. 342, 1960-1968.
17. Kowaltowski A.J., Castilho R.F. and Vercesi A.E. (2001). Mitochondrial permeability transition and oxidative stress. FEBS Lett. 495, 12-15.
18. Le Bras M., Clement M.W., Pervaiz S. and Brenner C. (2005). Reactive oxygen species and the mitochondrial signaling. Histol. Histopathol. 20, 205-219.
19. Lee H.C., Park I.C., Park M.J., An S., Woo S.H., Jin H.O., Chung H.Y., Lee S.J., Gwak H.S., Hong Y.J., Yoo D.H., Rhee C.H. and Hong S.I. (2005). Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J. Cell Biochem. 94, 597-610.
20. Li W.G., Stoll L.L., Rice J.B., Xu S.P., Miller F.J. Jr, Chatterjee P., Hu L., Oberley L.W., Spector A.A. and Weintraub N.L. (2003). Activation of NAD(P)H oxidase by lipid hydroperoxides: mechanism of oxidant-mediated smooth muscle cytotoxicity. Free Radic. Biol. Med. 34, 937-946.
21. Lim J.T., Joe A.K., Suzui M., Shimizu M., Masuda M. and Weinstein I.B. (2006). Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells. Clin. Cancer Res. 12, 3478-3484.
22. Mercurio F. and Manning A.M. (1999) NF-kappaB as a primary regulator of the stress response. Oncogene. 18, 6163-6171.
23. Minami T., Adachi M., Kawamura R., Zhang Y., Shinomura Y. and Imai K. (2005). Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin. Cancer Res. 11, 5248-5256.
24. Niki E., Yamamoto Y., Takahashi M., Komuro E. and Miyama Y. (1989). Inhibition of oxidation of biomembranes by tocopherol. Ann. NY Acad. Sci. 570, 23-31.
25. Park S.J, Wu C.H, Gordon J.D, Zhong X, Emami A, and Safa A.R. (2004). Taxol induces caspase-10-dependent apoptosis. J. Biol. Chem. 279, 51057-51067.
26. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J. and Huang P. (2003). Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278, 37832-37839.
27. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Li H., Stoumen A.L., Pamukcu R. and Ahnen D.J. (1997). Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57, 2452-2459.
28. Rice P.L., Kelloff J., Sullivan H., Driggers L.J., Beard K.S., Kuwada S., Piazza G. and Ahnen D.J. (2003). Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol. Cancer Ther. 2, 885-892.
29. Rice P.L., Beard K.S., Driggers L.J. and Ahnen D.J. (2004). Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res. 64, 8148-8151.
30. Rice P.L., Peters S.L., Beard K.S. and Ahnen D.J. (2006). Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways. Mol. Cancer Ther. 5, 746-754.
31. Sekiguchi M. and Tsuzuki T. (2002). Oxidative nucleotide damage: consequences and prevention. Oncogene 21,8895-8904.
32. Soh J.W., Mao Y., Kim M.G., Pamukcu R., Li H., Piazza G.A., Thompson W.J. and Weinstein I.B. (2000) Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin. Cancer Res. 6, 4136-4141.
33. Subbegowda R. and Frommel T.O. (1998). Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res. 58, 2772-2776.
34. Ushio-Fukai M. and Alexander R.W. (2004). Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol. Cell Biochem. 264, 85-97.
35. Verheul H.M., Panigrahy D., Yuan J. and D'Amato R.J. (1999). Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br. J. Cancer 79, 114-118.
36. Warner T.D, Giuliano F, Vojnovic I, Bukasa A, Mitchell J.A and Varie J.R. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 96, 7563-7568.
37. Xiao D., Deguchi A., Gundersen G.G., Oehlen B., Arnold L. and Weinstein I.B. (2006). The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. Mol. Cancer Ther. 5, 60-67.
38. Yamamoto Y., Yin M.J., Lin K.M. and Gaynor R.B. (1999). Sulindac Inhibits Activation of the NF-B Pathway. J. Biol. Chem. 74, 27307-27314.
39. Yang W., Velcich A., Mariadason J., Nicholas C., Corner G., Houston M., Edelmann W., Kucherlapati R., Holt P.R. and Augenlicht L.H. (2001). p21(WAF1/cip1)is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res. 1, 6297-6302.
40. Yang W., Bancroft L. and Augenlicht L.H. (2005). Methylation in the p21WAF1/cip1 promoter of Apc+/-, p21+/- mice and lack of response to sulindac. Oncogene 24, 2104-2109.
41. Yasui H., Adachi M. and Imai K. (2003). Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice. Cancer 97, 1412-1420.
42. Yip-Schneider M.T., Nakshatri H., Sweeney C.J., Marshall M.S., Wiebke E.A. and Schmidt C.M. (2005). Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol. Cancer Ther. 4, 587-594.
43. Yu C., Rahmani M., Dent P. and Grant S. (2004). The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp. Cell Res. 295, 555-566.
44. Zhang X., Morham S.G., Langenbach R. and Young D.A. (1999). Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190, 451-459.